Watch Alpha Tau Medical Ltd for free: we tell you when fair value or trend changes.

Alpha Tau Medical Ltd (DRTS) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Alpha Tau Medical Ltd, from audited financials.

Price: $13.72. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.

Revenue growth (quarter YoY) 0.0% (industry 0.0%)

Growth analysisrevenue history, year by year Quality 35/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0011839383

Thin data Nov 7, 2026

Alpha Tau Medical Ltd

DRTS · US

Low debt

Insiders sold $1.6M (6M)

Quality 35/100

Negative free cash flow

Trails peers (2/7)

Narrow moat 6/100 · thin data

Thin data

No fair value

Watch Alpha Tau Medical Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.

Show moreShow less

Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.

The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 34

Are margins and returns getting better?

Cashflow 8

Do the profits arrive as real cash?

Financial strength 87

Debt, balance sheet and risk of trouble

Investment 100

Does it invest with discipline instead of growing at any price?

Low Volatility 20

How calm the share price moves, does not count

Price momentum 84

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 93

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $1.6M and none bought.

SaleRaphi LevyChief Financial Officer9× since Jun 3, 2026: 132,871 shares, avg. $11.76$1.6MAug 21, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch DRTS, get fair value alerts →

Compare Alpha Tau Medical Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 2/6 measures

Overall it trails its industry peers.

Valuation

Quality Score 35 · Below median

Profitability

Return on assets −40.0% · Bottom 25%

Operating margin (12 months) 0.0% · Above median

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Balance sheet

Debt / equity 0.08× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 16.19× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)96 · sector 97

DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Incyte Corporation INCY	$119.65	$199.23	+67%	vs DRTS
Regeneron Pharmaceuticals, Inc REGN	$904.35	$1,275	+41%	vs DRTS
Genmab A/S GMAB	kr 3,527	kr 3,999	+13%	vs DRTS
WuXi Biologics (Cayman) Inc 2269	HK$47.62	HK$53.55	+12%	vs DRTS
Samsung Biologics Co 207940	1,516,000 KRW	1,667,600 KRW	+10%	vs DRTS
Vertex Pharmaceuticals Incorporated VRTX	$547.09	$596.75	+9%	vs DRTS
argenx SE ARGX	$927.21	$908.40	−2%	vs DRTS
CSL Limited CSL	A$202.04	A$183.04	−9%	vs DRTS
Celltrion, Inc 068270	211,000 KRW	74,945 KRW	−64%	vs DRTS
Royalty Pharma plc RPRX	$67.30	$19.01	−72%	vs DRTS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

Frequently asked questions

What is the quality score of DRTS?

Alpha Tau Medical Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

How solid is the balance sheet of Alpha Tau Medical Ltd (DRTS)?

Balance-sheet figures for Alpha Tau Medical Ltd (as of Nov 7, 2026): return on equity −141.7%, debt of 0.08 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.

Which stocks are comparable to Alpha Tau Medical Ltd?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

What is the share price of Alpha Tau Medical Ltd (DRTS)?

The closing price on Nov 6, 2026 was $13.72. We carry closing prices from our data provider, not a live tick.

Key figures of Alpha Tau Medical Ltd

How large is the market capitalisation of Alpha Tau Medical Ltd (DRTS)?

The market capitalisation of Alpha Tau Medical Ltd is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Alpha Tau Medical Ltd (DRTS)?

Earnings per share at Alpha Tau Medical Ltd are $−1.04. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Alpha Tau Medical Ltd (DRTS)?

The return on equity (ROE) of Alpha Tau Medical Ltd is −142% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Alpha Tau Medical Ltd (DRTS)?

On an EBIT basis the return on assets of Alpha Tau Medical Ltd is −21.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much free cash flow does Alpha Tau Medical Ltd (DRTS) generate?

The free cash flow of Alpha Tau Medical Ltd is −$32.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Alpha Tau Medical Ltd (DRTS) hold?

Alpha Tau Medical Ltd holds more cash than debt, $2.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Alpha Tau Medical Ltd in the live analysis

One click puts Alpha Tau Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.